In situ gene expression analysis of cancer using laser capture microdissection, microarrays and real time quantitative PCR.
The simultaneous development of laser capture microdissection (LCM) and high-throughput mRNA analysis platforms has provided a significant technological advance in the world of cancer biology. The combination of such technologies provides a unique and powerful opportunity to directly assess the in situ molecular genetic events that are associated with initiation and progression of human malignancies. Despite these technological advances, the integration of LCM with high-throughput gene expression analysis has been met with various challenges. The goal of this review is to highlight some of the obstacles that we have faced and continue to face as we try to optimally apply LCM to in situ gene expression analysis.
Elkahloun
Abdel G
AG
Cancer Genetics Branch, NHGRI-NIH, Bethesda, MD 20892, USA. abdel@nhgri.nih.gov
Gaudet
Justin
J
Robinson
Gregory S
GS
Sgroi
Dennis C
DC
D015972:Gene Expression Regulation, Neoplastic; D005821:Genetic Techniques; D006801:Humans; D007834:Lasers; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*
D012333:RNA, Messenger